Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Milei Threatens Falkland Oil Firms With Sanctions 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Add as a preferred source on Google
SOUTH SAN FRANCISCO, Calif., March 01, 2018 -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that it will host a conference call on Thursday, March 8th, 2018 at 1:30 p.m. Pacific Time to discuss corporate updates and financial results for the fourth quarter and year ended December 31, 2017.
The call can be accessed by dialing (844) 269-7720 (U.S. and Canada) or (574) 990-1148 (international), and entering passcode 8182338.
To access the live audio webcast, or the subsequent archived recording, visit the "Investors and Media - Calendar of Events" section of the Sunesis website at http://ir.sunesis.com. The webcast will be recorded and available for replay on the company's website for two weeks.
About Sunesis Pharmaceuticals
Sunesis is a biopharmaceutical company developing new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built an experienced cancer drug development organization committed to improving the lives of people with cancer. The Company is focused on advancing its novel kinase-inhibitor pipeline, with an emphasis on establishing proof of concept that its oral non-covalent BTK-inhibitor vecabrutinib is effective in ibrutinib-resistant chronic lymphocytic leukemia. Vecabrutinib is currently being evaluated in a Phase 1b/2, open-label, sequential-group, dose-escalation and cohort-expansion study in adults with chronic lymphocytic leukemia and other B-cell malignancies who have progressed after prior therapies. Beyond the development of vecabrutinib, the Company has two other kinase inhibitor programs, including the Takeda-partnered pan-RAF inhibitor TAK-580, which is in solid tumor trials, and Sunesis’ proprietary preclinical PDK1 inhibitor SNS-510, which is in preclinical development with an IND submission planned in 2019. PDK1 is a master kinase that activates other kinases important to cell growth and survival including members of the AKT, PKC, RSK and SGK families.
For additional information on Sunesis, please visit www.sunesis.com.
SUNESIS and the logos are trademarks of Sunesis Pharmaceuticals, Inc.
| Investor and Media Inquiries: Maeve Conneighton Argot Partners 212-600-1902 | Willie Quinn Sunesis Pharmaceuticals Inc. 650-266-3716 | ||
